Adoptive cell-mediated immunotherapy with interleukin-2 (IL-2) for relapsing lymphoblastic crisis following mismatched unrelated bone marrow transplantation in a chronic myelogenous leukemia patient.

Varadi, G; Ackerstein, A; Ben-Neriah, S; Nagler, A

Varadi, G; Ackerstein, A; Ben-Neriah, S; Nagler, A.

Affiliation

Varadi G; Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel.

Bone Marrow Transplant ; 21(1): 93-6, 1998 Jan.

Article in En | MEDLINE | ID: mdl-9486502

Subject(s)

Blast Crisis/therapy; Bone Marrow Transplantation; Immunotherapy, Adoptive; Interleukin-2/therapeutic use; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy; Adult; Bone Marrow Transplantation/adverse effects; Bone Marrow Transplantation/immunology; Female; Graft vs Host Disease/etiology; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Blast Crisis / Immunotherapy, Adoptive / Bone Marrow Transplantation / Interleukin-2 Type of study: Etiology_studies Limits: Adult / Female / Humans Language: En Journal: Bone Marrow Transplant Year: 1998 Document type: Article

Search on Google

XML

PubMed Links